Inogen reported total revenue of $81.7 million for the fourth quarter of 2025, a 2% increase compared to the same period last year, primarily driven by higher growth in international ...

Noted a shift of large customer orders from Q4 2025 into the first half of 2026 due to customer capital and budgeting ...

Developed in collaboration with Yuwell Medical, Voxi 5 presents a viable option for patients seeking reliable stationary oxygen therapy, delivering 1-5 L/min of quiet 1, pure 2, continuous flow oxygen ...

Inogen (NASDAQ:INGN) executives highlighted improving profitability, international momentum, and a broadened product ...

For the year, the company reported a loss of $22.7 million, or 86 cents per share. Revenue was reported as $348.7 million. Inogen expects full-year revenue in the range of $366 million to $373 million ...

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of ...

Home respiratory is a cornerstone of the HME industry, but manufacturers and providers are redefining what success in the market looks like: Oxygen therapy that keeps pace with patients, durable ...

Needham analyst Mike Matson downgraded the rating on Inogen, Inc (NASDAQ:INGN) to Hold from Buy, with a price target of $26. INGN announced it is acquiring privately-held Physio-Assist SAS for $32 ...